COVID 19 Disease. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group receive methylene blue in addition to conventional therapies (corticosteroids, anticoagulants, remdesivir, and antibiotics). Methylene blue i
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: The patient has received remdesivir and corticosteroids and antibiotics and anticoagulants At least one day and at most 5 days have passed since the patient's hospitalization. O2 saturation for 10 minutes without oxygen is less than 89 and more than 75 Age between 18 to 75 year Does not have a history of G6PD Deficiency Absence of chronic renal failure with GFR 45 The patient is not intubated Does not have systolic Blood Pressure <90 Do not take SSRI, MAO Inhibitor drugs Has not received plasma therapy, IVIG, hemoperfusion, Tocilizumab and plasmapheresis before administration of methylene blue Does not be pregnant The patient should be conscious
Exclusion criteria
Exclusion criteria: Patient dissatisfaction History of allergy or gastrointestinal intolerance to methylene blue
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality. Timepoint: One month after entering the study. Method of measurement: Patient death. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Zahra-Sadat Sanei
Mashhad University of Medical Sciences
Outcome results
None listed